Despite previous reports showing that FC/HV could promote cell adhesion and migration, we did not observe such behavior in our studies with FC/HV. Based on our results, the peptide might promote transient adhesion, as evidenced by our observation of spread cells 1 day after incubation on FC/HV treated plates. Although FC/HV did induce Erk1/2 activation, we observed no statistically significant increase in angiogenesis or arteriogenesis in the FC/HV treated rats. It is possible that FC/HV is inducing Erk1/2 activation in the cells already present within the MI region, but the inability of the peptide to promote significant endothelial cell migration and cell proliferation as LRRK2-IN-1 compared to the other 3 peptides studied may limit its ability to induce any dramatic neovascular formation. In conclusion, Ab-targeted BAPTA-AM ECM-derived peptides can be used to alter the myocardial microenvironment and promote the induction of angiogenesis in the injury site after a MI. The exact mechanisms by which the ECM peptides induced the observed in vivo angiogenic response, however, warrant further study. Furthermore, from our echocardiography data only Hep III prevented negative remodeling of the LV following a MI, indicating that neovascularization alone is insufficient to get full recovery of LV function. Perhaps by combining this ECM peptide therapy with cell therapy, we may be able to get full restoration of cardiac function and tissue. Nevertheless, our results present a new non-invasive strategy for regenerative therapies and a tool for investigating tissue repair and regeneration. Polycystic ovary syndrome is the most common endocrine disorder, affecting women of reproductive age with the prevalence ranging according to the National Institutes of Health criteria. PCOS is considered to be a metabolic syndrome with cardiovascular, insulin-dependent diabetes, dyslipidemia and endothelial dysfunction and visceral obesity risk factors. PCOS is characterised by chronic low-grade inflammation and it is likely to be responsible for metabolic abnormalities. Recently, it was reported that certain pro-inflammatory cytokines, such as interleukin-6, interleukin-17, tumor necrosis factor-a were elevated in women with PCOS, compared to systemically healthy individuals.